Here's an article on MediHelpline, Inc. SYP's investment and patent support.

[Press Nine] MediHelpline announced on the 25th that CEO Park Ok-nam won the "Gold Award," "Silver Award," and "World Intellectual Property Organization (WIPO) Special Award" at the "16th Korea Women's Invention Contest" held at KINTEX from July 20 to 23, 2023.

The 16th World Women's Invention Contest is an international competition hosted by the Korean Intellectual Property Office and officially sponsored by the World Intellectual Property Organization, with 330 people from 19 countries participating and exhibiting their inventions. Park Ok-nam won three awards, including the World Intellectual Property Organization Special Award, in recognition of his excellence in the technology.

The entries that won the Gold Prize and the World Intellectual Property Organization's Special Award are "an external composition for treating or preventing ulcers, TSLP inhibition and inflammatory skin diseases, wounds, inflammatory diseases, and arthritis containing combination biopharmaceutical extracts, including dragon's meat. It is a technology that can be applied from chronic to simple wounds of diabetic foot ulcers to natural materials of the mechanism of activating autophagy function in cells.

The silver-winning "body composition analysis method using 3D scans" is a technology that analyzes musculoskeletal imbalance (posture) and obesity by providing 3D body shape recognition and measurement reports with a single scan.

Park Ok-nam, CEO of the winner, said, "The diabetic foot ulcer treatment and mild cognitive impairment treatment based on this patent are in the second phase of clinical trials, and Parkinson's disease treatment is in the third phase of clinical trials."

Meanwhile, MediHelpline has completed a phase 2 clinical trial of Parkinson's disease with an autophagy-activated natural product material, and is preparing for phase 3 Parkinson's disease with approval from the Ministry of Food and Drug Safety in March 2022. In 2023, it was approved for a phase 2 clinical trial of mild cognitive impairment and a phase 2 clinical trial of diabetic foot ulcer.

The two entries were selected for the Ministry of Trade, Industry and Energy's task of developing drug-eluting dressing for the treatment of chronic wound (diabetic foot ulcer) in 2020 and the optical fusion human care technology development task of 3D human shape information analysis device technology (task number: 20016833).